Desoximetasone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Desoximetasone: From Inflammatory Skin Conditions to Alopecia Areata
One-Sentence Summary
Desoximetasone is a potent topical corticosteroid used for the treatment of inflammatory skin conditions such as eczema and psoriasis. The TxGNN model predicts it may be effective for Alopecia Areata (patchy hair loss driven by autoimmune attack on hair follicles), with 1 randomised controlled trial currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Inflammatory dermatoses (e.g., eczema, psoriasis) |
| Predicted New Indication | Alopecia Areata |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L2 |
| Canada Market Status | Not marketed |
| Number of DINs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacological information, desoximetasone is a high-potency topical corticosteroid (Class II) that exerts its effect through binding to intracellular glucocorticoid receptors, suppressing the transcription of pro-inflammatory cytokines — including IL-2 and IFN-γ — and inhibiting inflammatory cell infiltration around target tissues.
Alopecia areata is mediated by CD8⁺ T lymphocytes that breach the immune privilege of the hair follicle and trigger an autoimmune attack on the hair matrix. Topical corticosteroids are recognised as a first-line treatment in major clinical guidelines (AAD Guidelines for Alopecia Areata) precisely because they suppress this perifolliclular lymphocytic infiltration, restore the immune-privileged status of the follicle, and allow hair regrowth. The mechanistic link between desoximetasone’s anti-inflammatory action and the pathophysiology of alopecia areata is therefore high.
This makes the TxGNN prediction biologically coherent: desoximetasone is being used for a condition that shares the same target tissue (skin) and a partially overlapping mechanism (local immune suppression). The existence of a published randomised double-blind placebo-controlled trial specifically for desoximetasone 0.25% cream in alopecia areata further reinforces that this is not a speculative prediction but a clinically explored direction.
Clinical Trial Evidence
Currently no related clinical trials registered on ClinicalTrials.gov or ICTRP for desoximetasone in alopecia areata.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11030789 | 2000 | RCT | Archives of Dermatology | Randomised double-blind placebo-controlled trial evaluating 0.25% desoximetasone cream in alopecia areata; directly tests the repurposing hypothesis in this indication |
Canada Market Information
Desoximetasone currently holds no Drug Identification Numbers (DINs) and is not marketed in Canada. No approved product listings are available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A completed randomised double-blind placebo-controlled trial (PMID 11030789) directly evaluated desoximetasone 0.25% cream in alopecia areata, providing Level 2 evidence and a mechanistically coherent basis for this indication; the biological rationale (suppression of CD8⁺ T cell–mediated perifolliclular inflammation) is well-established in AAD guidelines for topical corticosteroids as first-line therapy.
To proceed, the following is needed:
- Full-text review and extraction of efficacy outcomes (response rate, proportion achieving ≥50% hair regrowth) from PMID 11030789
- Detailed mechanism of action data from DrugBank (DG002 remediation)
- Safety profile data from the package insert / product monograph, including local adverse effects (skin atrophy, telangiectasia) relevant to scalp use (DG001 remediation)
- Assessment of the available topical formulation strength (0.25% cream) against commercially available comparators (e.g., clobetasol 0.05%, betamethasone valerate 0.1%) to contextualise potency positioning
- Registration of a confirmatory clinical trial or identification of additional published evidence to upgrade from L2 to L1 before a formal New Drug Submission to Health Canada
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.